Cell membrane modification for rapid display of bi-functional peptides: A novel approach to reduce complement activation

Open Cardiovascular Medicine Journal

Volumn 4, Issue , 2010, Pages 157-165

  Goga, Ledia ^a   Perez Abadia, Gustavo ^a   Pushpakumar, Sathnur B ^a   Cramer, Daniel ^a   Yan, Jun ^a   Todnem, Nathan ^a   Anderson, Gary ^a   Soni, Chirag ^a   Barker, John ^a   Maldonado, Claudio ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cell membrane; Complement; Complement inhibitors; Compstatin; Drug delivery; Ischemia; Liposomes; Reperfusion

Indexed keywords

1,2 DIOLEOYLGLYCERO 3 [[N (5 AMINO 1 CARBOXYPENTYL)IMINODIACETIC ACID]SUCCINYL]NICKEL; 2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT INHIBITOR; COMPSTATIN; DIOLEOYLPHOSPHATIDYLCHOLINE; GLYCEROPHOSPHOLIPID; LIPOSOME; NICKEL; POLYHISTIDINE TAG; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LIPID VESICLE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 78249272975     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010157     Document Type: Article

References (50)

1. [1] Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971; 133(4): 885-900.
2. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody C5a during myocardial infarction in pigs. Am J Physiol 1995; 268: H448-H457.
3. Smith GW, McArthur CJ, Simpson IJ. Circulating immune complexes in myocardial infarction. J Clin Lab Immunol 1983; 12(4): 197-9.
4. Weiser MR, Williams JP, Moore FD Jr, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and comment. J Exp Med 1996; 183(5): 2343-8.
5. Platt JL, Saadi S. The role of complement in transplantation. Mol Immunol 1999; 36: 965-71.
6. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull 2004; 70:71-86.
7. Stahl GL, Xu Y, Hao L, et al. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 2003; 162(2): 449-5.
8. Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15(4): 369-96.
9. Harris CL, Fraser DA, Morgan BP. Tailoring anti-complement therapeutics. Biochem Soc Trans 2002; 30: 1019-26.
10. Smith GP, Smith RA. Membrane-targeted complement inhibitors. Mol Immunol 2001; 38(2-3): 249-55.
11. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000; 43(11): 2590-7.
12. Patel H, Smith RA, Sacks SH, Zhou W. Therapeutic strategy with a membrane-localizing complement regulator to increase the number usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006; 17(4): 1102-11.
13. Rehrig S, Fleming SD, Anderson J, et al. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol 2001; 167(10): 5921-7.
14. Stammberger U, Hamacher J, Hillinger S, Schmid RA. sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation. J Thorac Cardiovasc Surg 2000; 120(6):1078-84.
15. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25(11): 1265-75.
16. Pagano RE, Weinstein JN. Interactions of liposomes with mammalian cells. Annu Rev Biophys Bioeng 1978; 7: 435-68.
17. Banerjee R. Liposomes: Applications in medicine. J Biomater Appl 2001; 16(3): 3-21.
18. van Broekhoven CL, Parish CR, Vassiliou G, Altin JG. Engrafting costimulator molecules onto tumor cell surfaces with chelator lipids: a potentially convenient approach in cancer vaccine development. J Immunol 2000; 164(5): 2433-43.
19. Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem 2006; 49(15): 4616-22.
20. Klepeis JL, Floudas CA, Morikis D, et al. Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J Am Chem Soc 2003; 125(28): 8422-3.
21. [21] Morikis D, Roy M, Sahu A, et al. The structural basis of compstatin activity examined by structure-function-based design of peptide logs and NMR. J Biol Chem 2002; 277(17): 14942-1494253.
22. Soulika AM, Morikis D, Sarrias MR, et al. Studies of structureactivity relations of complement inhibitor compstatin. J Immunol 2003; 171(4): 1881-90.
23. Mallik B, Katragadda M, Spruce LA, et al. Design and NMR characterization of active analogues of compstatin containing nonnatural amino acids. J Med Chem 2005; 48(1): 274-86.
24. Morgan BP. Methods in molecular biology. 1st ed. Totowa, NJ: Humana Press Inc. 2000.
25. Roederer M, Treister A, Moore W, Herzenberg LA. Probability binning comparison: a metric for quantitating univariate distribution differences. Cytometry 2001; 45(1): 37-46.
26. Zhang F, Schmidt WG, Hou Y, Williams AF, Jacobson K. Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc Natl Acad Sci USA 1992; 89(12): 5231-5.
27. Wahlsten JL, Mills CD, Ramakrishnan S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J Immunol 1998; 161(12): 6761-7.
28. Chen A, Zheng G, Tykocinski ML. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J Immunol 2000; 164(2): 705-11.
29. Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002; 17(6): 795-808.
30. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997; 54(Suppl 4): 8-14.
31. [31] Fraley R, Straubinger RM, Rule G, Springer EL, Papahadjopoulos D. Liposome-mediated delivery of deoxyribonucleic acid to cells: enhanced efficiency of delivery related to lipid composition and incubation conditions. Biochemistry 1981; 20(24): 6978-87.
32. Garrett FE, Goel S, Yasul J, Koch RA. Liposomes fuse with sperm cells and induce activation by delivery of impermeant agents. Biochim Biophys Acta 1999; 1417(1): 77-88.
33. Kozubek A, Gubernator J, Przeworska E, Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47(3): 639-49.
34. Schiffelers R, Storm G, Bakker-Woudenberg I. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 2001; 48(3): 333-44.
35. Trigiante G, Huestis WH. Selective virus-mediated intracellular delivery of membrane-impermeant compounds by means of plasma membrane vesicles. Antiviral Res 2000; 45(3): 211-21.
36. Khatri K, Rawat A, Mahor S, Gupta PN, Vyas SP. Hepatitis B surface protein docked vesicular carrier for site specific delivery to liver. J Drug Target 2005; 13(6): 359-66.
37. Zakaria eR, Ehringer WD, Tsakadze N, Li N, Garrison RN. Direct energy delivery improves tissue perfusion after resuscitated shock. Surgery 2005 138(2):195-203.
38. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148(7): 2207-2216.
39. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med 1992; 119(6): 598-620.
40. Kalayoglu M, Sollinger HW, Stratta RJ, et al. Extended preservation of the liver for clinical transplantation. Lancet 1988; 1(8586): 617-9.
41. Lominadze D, Saari JT, Miller FN, Catalfamo JL, Schuschke DA. Von Willebrand factor restores impaired platelet thrombogenesis in copper-deficient rats. J Nutr 1997; 127(7): 1320-7.
42. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249(4965): 146-51.
43. Wink DA, Wink CB, Nims RW, Ford PC. Oxidizing intermediates generated in the Fenton reagent: kinetic arguments against the intermediacy of the hydroxyl radical. Environ Health Perspect 1994; 102(Suppl 3): 11-15.
44. Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol 2002; 23(2): 61-4.
45. Pratt JR, Hibbs MJ, Laver AJ, Smith RA, Sacks SH. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996; 149(6): 2055-66.
46. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97(22): 2259-67.
47. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4(3): 359-95.
48. Sullivan KE. Complement deficiency and autoimmunity. Curr Opin Pediatr 1998; 10(6): 600-6.
49. Dong J, Pratt JR, Smith RA, Dodd I, Sacks SH. Strategies for targeting complement inhibitors in ischaemia/reperfusion injury. Mol Immunol 1999; 36(13-14): 957-63.
50. Zacharowski K, Otto M, Hafner G, Marsh HC, Jr, Thiemermann C. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br J Pharmacol 1999; 128(5): 945-52.